Dermata Therapeutics, Inc.
DRMA
$5.50
-$0.33-5.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 32.05% | -33.95% | -7.08% | -9.32% | -2.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.53% | -26.96% | 44.17% | 78.02% | 66.46% |
| Operating Income | 38.53% | 26.96% | -44.17% | -78.02% | -66.46% |
| Income Before Tax | 39.87% | 26.50% | -47.65% | -84.57% | -66.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.87% | 26.50% | -47.65% | -84.57% | -66.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.87% | 26.50% | -47.65% | -84.57% | -66.28% |
| EBIT | 38.53% | 26.96% | -44.17% | -78.02% | -66.46% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 96.04% | 93.67% | 86.27% | 74.77% | 55.68% |
| Normalized Basic EPS | 96.04% | 93.67% | 86.27% | 74.77% | 55.68% |
| EPS Diluted | 96.04% | 93.67% | 86.27% | 74.77% | 55.68% |
| Normalized Diluted EPS | 96.04% | 93.67% | 86.27% | 74.77% | 55.68% |
| Average Basic Shares Outstanding | 1,416.25% | 1,061.04% | 974.06% | 630.05% | 276.11% |
| Average Diluted Shares Outstanding | 1,416.25% | 1,061.04% | 974.06% | 630.05% | 276.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |